Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Climb 5.3% – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price rose 5.3% on Friday. The stock traded as high as $22.07 and last traded at $21.6050. Approximately 6,807 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 264,451 shares. The stock had previously closed at $20.52.

Analysts Set New Price Targets

Several research analysts have commented on CHGCY shares. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Tuesday, September 1st. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

The stock has a 50 day moving average price of $20.76 and a 200 day moving average price of $22.89. The company has a market cap of $70.83 billion, a P/E ratio of 23.39 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings data on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. The business had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. As a group, equities research analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.